MedTrace Logo

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.

NCT04189055 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-06-12

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease.

Patients will be included in cohort #1 or cohort #2. The inclusion in cohort #2 will start when the results of the cohort #1 are available.

Patient will receive either cetuximab alone (cohort #1) or cetuximab with irinotecan (cohort #2).

Conditions

  • Cancer Colorectal

Interventions

DRUG

Cetuximab

Cetuximab 500mg/m² IV, day 1

DRUG

Irinotecan

Irinotecan 180mg/m² IV, day 1

Sponsors & Collaborators

  • Hôpital Franco-Britannique-Fondation Cognacq-Jay

    lead OTHER

Principal Investigators

  • Benoist CHIBAUDEL, MD · Franco-British Hospital - GCS IHFB Cognacq-Jay

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-07
Primary Completion
2024-04-30
Completion
2024-07-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04189055 on ClinicalTrials.gov